Acorda to regain global commercialization rights to FAMPYRA by Jan 2025

Acorda Therapeutics ( NASDAQ: ACOR ) today announced it will regain global commercialization rights to FAMPYRA following a decision by Biogen ( BIIB ) to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis with walking disability.

Acorda plans to assume commercialization responsibilities as soon as possible during 2024 as marketing authorization transfers and distribution arrangements are finalized for each territory. Source: Press Release More on Acorda Therapeutics Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript Acorda Therapeutics, Inc.

2023 Q3 Results Earnings Call Presentation Acorda Therapeutics GAAP EPS of $7.16, revenue of $27.72M Financial information for Acorda Therapeutics.